Found 12 articles
Notably, Koselugo was studied in pediatric populations first, a reversal of the typical development path taken by the majority of drugs.
She takes over the role held by oncology research legend José Baselga, who passed away in March from a neurodegenerative disease.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
IND cleared for Phase 2 study of CGT9486, a selective mutant KIT inhibitor, in Advanced Systemic Mastocytosis patients John Robinson, PhD appointed as Chief Scientific Officer to lead newly created Cogent Research team Evan Kearns, JD joined Cogent as Chief Legal Officer Ended Q1 2021 with $230.7 million in cash, sufficient to fund operations into 2024
Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million supports company goals into 2024, including three CGT9486 clinical trials on-track to start this year, beginning with ASM in 1H21
June 28 virtual event to honor those making extraordinary strides to improve the lives of patients and families impacted by rare diseases
LYNPARZA® (olaparib) Improved Median Time Patients Lived Without Disease Progression to Over Four and Half Years in BRCA-mutated Advanced Ovarian Cancer vs. Just Over One Year With Placebo
Five-year data from the SOLO-1 Phase III trial is the longest follow-up analysis for any PARP inhibitor in the 1st-line maintenance setting
First-Quarter 2020 Worldwide Sales Were $12.1 Billion, an Increase of 11%; Excluding the Impact from Foreign Exchange, Sales Grew 13%
KOSELUGO™ (selumetinib) Approved for the Treatment of Neurofibromatosis Type 1-associated Plexiform Neurofibromas in Pediatric Patients, Available from Onco360
Onco360 ® , the nation’s largest independent Oncology Pharmacy, has been selected by AstraZeneca to be a specialty pharmacy partner for KOSELUGO™ (selumetinib), a novel oral kinase inhibitor indicated for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. “The approval of KOSELUGO represents a new treatment st
KOSELUGO™ (selumetinib) Approved In US For Pediatric Patients With Neurofibromatosis Type 1 Plexiform Neurofibromas
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US announced that the US Food and Drug Administration has approved the kinase inhibitor KOSELUGO™ for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.
KOSELUGO® (selumetinib) Approved by FDA for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas
AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration has approved the kinase inhibitor KOSELUGO for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.
Today, the U.S. Food and Drug Administration approved Koselugo (selumetinib) for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1), a genetic disorder of the nervous system causing tumors to grow on nerves.